UNC researchers find 'vulnerability' in lung cancer; could lead to new treatments
Researchers at UNC-Chapel Hill say they've found a new "vulnerability" in a common form of lung cancer that could provide a promising target for a new treatment. (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - September 27, 2020 Category: Pharmaceuticals Authors: Seth Thomas Gulledge Source Type: news

UNC researchers find 'vulnerability' in lung cancer; could lead to new treatments
Researchers at UNC-Chapel Hill say they've found a new "vulnerability" in a common form of lung cancer that could provide a promising target for a new treatment. (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - September 27, 2020 Category: Biotechnology Authors: Seth Thomas Gulledge Source Type: news

Meet Bob - living proof that lung cancer isn't the death sentence it once was
Today it is still the UK's biggest cancer killer, accounting for one in five of all cancer deaths, but now - at last - for patients like Bob Pain, pictured, there is reason for hope. (Source: the Mail online | Health)
Source: the Mail online | Health - September 26, 2020 Category: Consumer Health News Source Type: news

UNC researchers find 'vulnerability' in lung cancer; could lead to new treatments
Researchers at UNC-Chapel Hill say they've found a new "vulnerability" in a common form of lung cancer that could provide a promising target for a new treatment. (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - September 25, 2020 Category: Biotechnology Authors: Seth Thomas Gulledge Source Type: news

Lorlatinib: Another First-Line Option for ALK-Positive NSCLC? Lorlatinib: Another First-Line Option for ALK-Positive NSCLC?
First-line lorlatinib significantly prolonged progression-free survival compared with crizotinib in advanced ALK-positive nonsmall cell lung cancer, according to a phase 3 interim analysis.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - September 24, 2020 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

A Glimmer of Hope for Immunotherapy in SCLC? A Glimmer of Hope for Immunotherapy in SCLC?
While combination immunotherapy did not show a survival benefit after chemoradiotherapy in small cell lung cancer, longer follow-up and biomarker analysis may reveal some gains, suggests trial data.Medscape News UK (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - September 23, 2020 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

What Your Blood Tells You About Cancer
Blood tests can tell us a lot about what’s going on in our bodies—from whether we’re eating too much sugar to whether we’re harboring any infectious diseases. Scientists lately have been working on ways to use similar diagnostic tools for cancer, which have the potential to dramatically increase the amount of information doctors use to figure out the best treatments for their patients. Called liquid biopsies, these tests are designed to pick up genetic material shed by cancer tumors into the blood, which lets doctors avoid the invasive procedures needed to extract samples directly from tumors. That ...
Source: TIME: Health - September 22, 2020 Category: Consumer Health News Authors: Alice Park Tags: Uncategorized Source Type: news

Radiosurgery Appears to Benefit Old & Young With Brain Metastases Radiosurgery Appears to Benefit Old & Young With Brain Metastases
Stereotactic radiosurgery provides similar overall survival in patients older and younger than 75 years who have brain metastases from lung cancer, according to a retrospective study from Japan.Reuters Health Information (Source: Medscape Radiology Headlines)
Source: Medscape Radiology Headlines - September 22, 2020 Category: Radiology Tags: Hematology-Oncology News Source Type: news

Health groups urge caution on COVID-19 vaccine
The American College of Radiology is one of almost 100 health organizations...Read more on AuntMinnie.comRelated Reading: ACR to coordinate imaging for large COVID-19 study ACR Data Science Institute drafts model API ACR taps new executive director for Neiman HPI ACR: New USPSTF lung cancer guidelines will save lives ACR, RSNA call on FDA to hold off on autonomous AI (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - September 21, 2020 Category: Radiology Source Type: news

Sotorasib Is a'Triumph of Drug Discovery' in Cancer Sotorasib Is a'Triumph of Drug Discovery' in Cancer
The drug inhibits KRAS p.G12C-mutant tumors, which are seen in about 13% of patients with non-small cell lung cancer.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - September 21, 2020 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

No benefit for post-operative radiotherapy in non-small-cell lung cancer
(European Society for Medical Oncology) Post-operative radiotherapy (PORT) used in patients with non-small-cell lung cancer (NSCLC) following complete resection and after (neo) adjuvant chemotherapy shows no statistically significant difference in 3-year disease-free survival (DFS), according to data presented at ESMO 2020. These results give the oncology community a long-awaited answer. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - September 20, 2020 Category: International Medicine & Public Health Source Type: news

Ruth Bader Ginsburg Dies from Pancreatic Cancer
The three-time cancer survivor faced her most recent troubles in late 2018, when she had surgery for lung cancer that was discovered after she broke several ribs in a fall in her chambers. In January of 2020, Ginsburg announced that she was cancer free. But in July she said she was undergoing chemotherapy after a lesion was found on her liver. (Source: WebMD Health)
Source: WebMD Health - September 19, 2020 Category: Consumer Health News Source Type: news

AI can enhance evaluation of cancer response over time
Radiology reports created with help from artificial intelligence (AI) are more...Read more on AuntMinnie.comRelated Reading: C-MIMI: AI peer review can spot missed lung cancer C-MIMI: Use of AI in radiology is evolving SNMMI 2020: AI analysis of PET could help classify prostate cancer SIIM 2020: Human element shouldn't be neglected with AI AI Metrics joins forces with Imaging Biometrics (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - September 18, 2020 Category: Radiology Source Type: news

Lung Cancer Treatment Plans Changed Due to Pandemic
57 percent of patients receiving active treatment had at least one change in treatment plans (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - September 18, 2020 Category: Cancer & Oncology Tags: Infections, Oncology, Pharmacy, Pulmonology, Journal, Source Type: news

Lung cancer symptoms - how to reveal your risk of a tumour by looking at your fingertips
LUNG cancer symptoms include difficulty breathing, headaches, and persistent chest pain. But you could also be at risk of a tumour if you develop a "surprising" sign on your fingers. This is the warning sign of lung cancer on your fingertips. Should you consider speaking to a doctor? (Source: Daily Express - Health)
Source: Daily Express - Health - September 18, 2020 Category: Consumer Health News Source Type: news

Roche receives positive CHMP opinion for Tecentriq in combination with Avastin for the treatment of people with the most common form of liver cancer
Basel, 18 September 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the European Medicines Agency ’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of Tecentriq® (atezolizumab) in combination with Avastin® (bevacizumab) for the treatment of adult patients with advanced or unresectable hepatocellular carcinoma (HCC) who have not received prior systemi c therapy. Based on this recommendation, a final decision regarding approval of Tecentriq in combination with Avastin in this disease setting, along with the full details of the approved indication, is expe...
Source: Roche Media News - September 18, 2020 Category: Pharmaceuticals Source Type: news

Roche receives positive CHMP opinion for Tecentriq in combination with Avastin for the treatment of people with the most common form of liver cancer
Basel, 18 September 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the European Medicines Agency ’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of Tecentriq® (atezolizumab) in combination with Avastin® (bevacizumab) for the treatment of adult patients with advanced or unresectable hepatocellular carcinoma (HCC) who have not received prior systemi c therapy. Based on this recommendation, a final decision regarding approval of Tecentriq in combination with Avastin in this disease setting, along with the full details of the approved indication, is expe...
Source: Roche Investor Update - September 18, 2020 Category: Pharmaceuticals Source Type: news

Lung Cancer Treatment Plans Changed Due to Pandemic
FRIDAY, Sept. 18, 2020 -- More than half of patients have experienced changes in their lung cancer treatment plan as a result of the COVID-19 pandemic, according to a research letter published online Sept. 17 in JAMA Oncology. Arielle Elkrief,... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - September 18, 2020 Category: Pharmaceuticals Source Type: news

17.09.20: ESMO Virtual Congress 2020:
New data reinforce strong clinical profile of Vitrakvi™ for patients of all ages with TRK Fusion Cancer including lung and thyroid tumors78% overall response rate (ORR) and median progression-free survival (PFS) of more than 3 years (36.8 months) demonstrate extended benefit in updated data set of 175 adults and children / Majority of adverse events were grade 1 or 2; no new safety signals identified / Consistently high ORRs shown in lung and thyroid data subsets (71 and 75%, respectively) as well as long durability (estimated duration of response at 12 months of 88% and 95%, respectively) / Among patients from integ...
Source: Bayer IR Newsfeed: Events - September 17, 2020 Category: Pharmaceuticals Source Type: news

Three-drug combo reduces risk for lung cancer by 17%, study finds
Taking aspirin, statins and the drug metformin together reduces the risk for lung cancer by 17%, a study published Thursday by the Journal of Thoracic Oncology found. (Source: Health News - UPI.com)
Source: Health News - UPI.com - September 17, 2020 Category: Consumer Health News Source Type: news

GAVRETO (pralsetinib), FDA Approved for Treatment of Metastatic RET Fusion-Positive Non-Small Cell Lung Cancer, Available at Biologics by McKesson
CARY, N.C., Sept. 17, 2020 —Biologics by McKesson, an independent specialty pharmacy specializing in oncology and rare disease areas, has been selected by Blueprint Medicines as a specialty pharmacy provider for GAVRETOTM (pralsetinib) for the treatment of adult patients with metastatic RET fusion-p... (Source: McKesson News)
Source: McKesson News - September 17, 2020 Category: Information Technology Source Type: news

Roche to present a broad range of data across multiple cancer types at the ESMO Virtual Congress 2020
Basel, 17 September 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that results from a number of studies across its broad oncology portfolio will be presented at the European Society for Medical Oncology (ESMO) Virtual Congress 2020, which will be held 19-21 September, 2020. Results include data from three phase III studies across the Tecentriq® (atezolizumab) triple-negative breast cancer (TNBC) programme. Central nervous system (CNS) efficacy data from integrated analyses of the pivotal phase II Rozlytrek® STARTRK-2, phase I STARTRK-1, and phase I ALKA-372-001 trials will be presented in addition to re...
Source: Roche Media News - September 17, 2020 Category: Pharmaceuticals Source Type: news

Roche to present a broad range of data across multiple cancer types at the ESMO Virtual Congress 2020
Basel, 17 September 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that results from a number of studies across its broad oncology portfolio will be presented at the European Society for Medical Oncology (ESMO) Virtual Congress 2020, which will be held 19-21 September, 2020. Results include data from three phase III studies across the Tecentriq® (atezolizumab) triple-negative breast cancer (TNBC) programme. Central nervous system (CNS) efficacy data from integrated analyses of the pivotal phase II Rozlytrek® STARTRK-2, phase I STARTRK-1, and phase I ALKA-372-001 trials will be presented in addition to re...
Source: Roche Investor Update - September 17, 2020 Category: Pharmaceuticals Source Type: news

Changes in lung cancer treatment during COVID-19 pandemic
(JAMA Network) Changes in   lung cancer treatment during the COVID-19 pandemic were evaluated in this study. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - September 17, 2020 Category: Cancer & Oncology Source Type: news

Three common medications lower risk and mortality for lung cancer
(International Association for the Study of Lung Cancer) Combined use of aspirin, statins, and metformin is associated with decreased lung cancerincidence and mortality, according to a study published in the Journal of Thoracic Oncology (JTO). The JTO is the official journal of the International Association for the Study of Lung Cancer. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - September 17, 2020 Category: Cancer & Oncology Source Type: news

60% of lung cancer patients saw COVID-19-related treatment delays, study finds
Nearly 60% of people undergoing treatment for lung cancer experienced disruptions in care this spring because of the COVID-19 pandemic, according to an analysis published Thursday by JAMA Oncology. (Source: Health News - UPI.com)
Source: Health News - UPI.com - September 16, 2020 Category: Consumer Health News Source Type: news

C-MIMI: AI peer review can spot missed lung cancer
A peer review process that's driven by artificial intelligence (AI) can identify...Read more on AuntMinnie.comRelated Reading: C-MIMI: Use of AI in radiology is evolving Medical imaging AI market projected for strong growth Can AI diagnose heart failure on chest x-rays? AI aids classification of indeterminate lung nodules Ferrum deploys AI platform for lung cancer detection (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - September 15, 2020 Category: Radiology Source Type: news

A scientific advance in studying early-stage lung cancer
(Boston Children's Hospital) Lung cancer is the leading cancer killer in the US. It is often missed in its earlier stages, and while recent imaging advances have enabled earlier detection, there are still no targeted treatments for early-stage lung cancers. New research from Boston Children's Hospital, in collaboration with Boston University and UCLA, provides an accelerated platform for identifying and testing potential treatments: 'organoids' created from lung cells. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - September 15, 2020 Category: Cancer & Oncology Source Type: news

NICE recommends lung cancer treatment
Thousands of people with non-small-cell lung cancer (NSCLC) will benefit from draft guidance published by NICE recommending osimertinib (also called Tagrisso and made by AstraZeneca) at two different places in the treatment pathway for locally advanced or metastatic epidermal growth factor receptor (EGFR)-positive NSCLC. (Source: NHS Networks)
Source: NHS Networks - September 15, 2020 Category: UK Health Source Type: news

Checkpoint Inhibitors: Sooner Than Later in Lung Cancer? Checkpoint Inhibitors: Sooner Than Later in Lung Cancer?
Checkpoint inhibitors may offer a'unique opportunity'to improve the cure rate in lung cancer, says Dr Mark Kris.Medscape Oncology (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - September 14, 2020 Category: Cancer & Oncology Tags: Hematology-Oncology Commentary Source Type: news

Mesothelioma Trial to Test Cancer Vaccine with Immunotherapy
A research team at Oslo University Hospital in Norway has opened a mesothelioma clinical trial using the novel UV1 cancer vaccine alongside a promising immunotherapy combination. UV1 is a peptide-based vaccine designed to induce a specific T-cell response and increase the effectiveness of the immunotherapy drugs. This is the first time UV1 will be studied with mesothelioma cancer, but it already has shown safety and signs of efficacy when used on malignant melanoma, prostate cancer and lung cancer in studies worldwide. It will be used with the immunotherapy combination of nivolumab and ipilimumab, also known by brand names...
Source: Asbestos and Mesothelioma News - September 14, 2020 Category: Environmental Health Authors: Fran Mannino Source Type: news

New study from MD Anderson and BridgeBio's Navire Pharma shows SHP2 inhibition overcomes multiple therapeutic-resistance mechanisms in lung cancer
(University of Texas M. D. Anderson Cancer Center) New preclinical research from MD Anderson and Navire finds a novel drug targeting SHP2 can overcome multiple paths of therapeutic resistance in lung cancer. Navire will launch a clinical trial of SHP2 inhibitors by the end of 2020. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - September 14, 2020 Category: Cancer & Oncology Source Type: news

Case Western partners with pharmaceutical giants on AI
Case Western Reserve University in Cleveland has partnered with pharmaceutical...Read more on AuntMinnie.comRelated Reading: AI can spot smokers at high risk of cancer on x-rays Case Western lands grant from NCI for AI research New treatments lead to drop in lung cancer deaths Holographic anatomy program shifts gears after COVID-19 AI can predict if COVID-19 patients will need ventilators (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - September 11, 2020 Category: Radiology Source Type: news

Drugmakers help Case Western Reserve researcher build AI tools to treat lung cancer
Artificial intelligence tools being developed at Case Western Reserve University in Cleveland to fight lung cancer are a step closer to human clinical trials, thanks to recent agreements with two pharmaceutical companies. (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - September 11, 2020 Category: Pharmaceuticals Authors: Mary Vanac Source Type: news

Drugmakers help Case Western Reserve researcher build AI tools to treat lung cancer
Artificial intelligence tools being developed at Case Western Reserve University in Cleveland to fight lung cancer are a step closer to human clinical trials, thanks to recent agreements with two pharmaceutical companies. (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - September 11, 2020 Category: Biotechnology Authors: Mary Vanac Source Type: news

CT radiomics predicts esophageal cancer outcomes
Machine-learning models that assess both peritumoral and intratumoral radiomics...Read more on AuntMinnie.comRelated Reading: PET radiomics tailor head/neck cancer treatment CT radiomics can predict COVID-19 pneumonia outcomes AI, radiomics can predict stroke treatment success Can radiomics improve CT lung cancer screening? AI can predict if COVID-19 patients will need ventilators (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - September 11, 2020 Category: Radiology Source Type: news

PNB Vesper gets nod to begin phase-2 clinical trials for COVID-19 drug
The molecule was initially developed for lung cancer, the company's promoter and chief executive P N Balaram told . The firm's labs are located in Britain. He said the company on Thursday received permission from the Central Licensing Authority under the Central Drugs Standard Organisation for the second phase of clinical trials. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - September 11, 2020 Category: Pharmaceuticals Source Type: news

Powerful push for AI for cancer immunotherapy
(Case Western Reserve University) The companies will provide biomedical engineer Anant Madabhushi and collaborators at NYU with chest CT scan and/or digital pathology images from completed clinical trials in which their specific immunotherapy drugs were tested on lung cancer patients. Madabhushi's lab's computational-imaging tools have shown " potential to predict an individual cancer patient's response to immunotherapy, " so the collaboration can help validate research and " advance efforts to get the right treatment to the patients who will benefit the most. " (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - September 10, 2020 Category: International Medicine & Public Health Source Type: news

Are clinicians ordering CT lung screening too often?
Referring providers are ordering CT lung cancer screening exams for individuals...Read more on AuntMinnie.comRelated Reading: Which smokers seek out CT lung cancer screening? Can radiomics improve CT lung cancer screening? AI aids classification of indeterminate lung nodules Education affects follow-up for CT lung screening exams AI converts low-dose CT scans to high-quality studies (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - September 9, 2020 Category: Radiology Source Type: news

Respiratory, Lung Cancer Death Up Even With Low-Intensity Smoking
WEDNESDAY, Sept. 9, 2020 -- Current low-intensity smokers have an increased risk for respiratory and lung cancer mortality, according to a study presented at the European Respiratory Society International Congress 2020, being held virtually from... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - September 9, 2020 Category: Pharmaceuticals Source Type: news

FDA approves pralsetinib for lung cancer with RET gene fusions
On September 4, 2020, the Food and Drug Administration granted accelerated approval to pralsetinib (GAVRETOTM, Blueprint Medicines Corporation) for adult patients with metastatic RET fusion-positive non-small cell lung cancer (NSCLC) as detected by an FDA approved test. (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - September 8, 2020 Category: Drugs & Pharmacology Authors: FDA Source Type: news

08.09.20: Not intended for U.S. and UK Media
Bayer to showcase new data from evolving Oncology portfolio at ESMO Virtual Congress 2020Long-term efficacy and safety results for larotrectinib (Vitrakvi™) from an integrated data set of adult and pediatric patients with TRK fusion cancer, as well as sub-analyses in advanced thyroid and lung cancer patients / Tolerability and treatment response data from the Phase III ARAMIS trial investigating darolutamide (Nubeqa™) in men with non-metastatic castration-resistant prostate cancer (nmCRPC) / Continued research to explore potential of marketed products, evaluating regorafenib (Stivarga™) and radium-223 dic...
Source: Bayer IR Newsfeed: Events - September 8, 2020 Category: Pharmaceuticals Source Type: news

Pralsetinib: Second Drug for RET+ NSCLC Approved in US Pralsetinib: Second Drug for RET+ NSCLC Approved in US
Another drug is now approved for use in patients with non-small cell lung cancer whose tumors harbor RET fusions, which are found in approximately 1% to 2% of cases.FDA Approvals (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - September 8, 2020 Category: Cancer & Oncology Tags: Hematology-Oncology News Alert Source Type: news

FDA Approves First NGS-Based Companion Diagnostic for RET Fusion-Positive Non-Small Cell Lung Cancer
CDx approval expands clinical utility of Oncomine Dx Target Test to identify candidates for GAVRETO CARLSBAD, Calif., Sept. 8, 2020 -- (Healthcare Sales & Marketing Network) -- The U.S. Food and Drug Administration (FDA) has granted premarket approval ... Diagnostics, Oncology, FDA Thermo Fisher Scientific, Oncomine Dx Target, NSCLC, GAVRETO, pralsetinib (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - September 8, 2020 Category: Pharmaceuticals Source Type: news

Targeted drug found effective in patients who have lung cancer with certain mutations
(Massachusetts General Hospital) A targeted therapy called capmatinib can provide significant benefits to patients who have advanced lung cancer with specific gene mutations, according to recently published results from a phase two clinical trial. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - September 8, 2020 Category: International Medicine & Public Health Source Type: news

Atezolizumab-associated Encephalitis in Metastatic Lung Cancer Atezolizumab-associated Encephalitis in Metastatic Lung Cancer
This case demonstrates encephalitis as an rare but potentially serious adverse event associated with the immune checkpoint inhibitor atezolizumab.Journal of Medical Case Reports (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - September 7, 2020 Category: Consumer Health News Tags: Family Medicine/Primary Care Journal Article Source Type: news

Roche announces FDA approval of Gavreto (pralsetinib) for the treatment of adults with metastatic RET fusion-positive non-small cell lung cancer
             Basel, 7 September 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the United States (US) Food and Drug Administration (FDA) has approved Gavreto ™ (pralsetinib) for the treatment of adults with metastatic rearranged during transfection (RET) fusion-positive non-small cell lung cancer (NSCLC) as detected by an FDA approved test. This indication was approved under the FDA’s Accelerated Approval programme, based on data from the phase I/II ARROW study. Continued approval for this indication may be contingent upon verifica...
Source: Roche Media News - September 7, 2020 Category: Pharmaceuticals Source Type: news

Roche announces FDA approval of Gavreto (pralsetinib) for the treatment of adults with metastatic RET fusion-positive non-small cell lung cancer
             Basel, 7 September 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the United States (US) Food and Drug Administration (FDA) has approved Gavreto ™ (pralsetinib) for the treatment of adults with metastatic rearranged during transfection (RET) fusion-positive non-small cell lung cancer (NSCLC) as detected by an FDA approved test. This indication was approved under the FDA’s Accelerated Approval programme, based on data from the phase I/II ARROW study. Continued approval for this indication may be contingent upon verifica...
Source: Roche Investor Update - September 7, 2020 Category: Pharmaceuticals Source Type: news

Mayo Clinic Q and A: Lung cancer care during the COVID-19 pandemic
DEAR MAYO CLINIC: My father has been a heavy smoker for most of his life. He was diagnosed with lung cancer recently. He underwent surgery and several chemotherapy treatments prior to the outbreak of COVID-19. He is getting a bit agitated being home, and we are wondering if it is safe for him to venture out [...] (Source: News from Mayo Clinic)
Source: News from Mayo Clinic - September 6, 2020 Category: Databases & Libraries Source Type: news

Role of Chest Radiographs in Early Lung Cancer Detection Role of Chest Radiographs in Early Lung Cancer Detection
Low-dose CT is traditionally used in the screening of patients at risk for lung cancer, but it has its limitations. Might chest radiography provide a viable alternative?Translational Lung Cancer Research (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - September 4, 2020 Category: Consumer Health News Tags: Hematology-Oncology Journal Article Source Type: news